News | December 18, 2023
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
10+ emerging markets, Japan & ANZ transition in final phase
10+ emerging markets, Japan & ANZ transition in final phase
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
New facility is part of Aptar Pharma’s global expansion program
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Currently, Venkat is Lead – Market Access, India at Pfizer
Subscribe To Our Newsletter & Stay Updated
